Nutriband Inc.'s Board of Directors approved and declared a 25% preferred stock dividend. Shareholders of record on July 25, 2025, will receive one preferred share for every four shares of common stock held, with a pay date of August 5, 2025.
Each preferred share will be convertible to one share of common stock following FDA approval of the company’s AVERSA Fentanyl product. If preferred shares remain unconverted, they will be entitled to an annual cash dividend paid from company profits, as decided by the Board of Directors.
CEO Gareth Sheridan stated that the core goal is to continue to create value for shareholders, particularly as the company nears commercialization of AVERSA Fentanyl. This dividend aligns shareholder interests directly with the key regulatory objective of FDA approval for its lead product.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.